Sofie Carmans Selected Research

Myelin-Oligodendrocyte Glycoprotein

2/2013

Systemic treatment with the inhibitory neurotransmitter γ-aminobutyric acid aggravates experimental autoimmune encephalomyelitis by affecting proinflammatory immune responses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sofie Carmans Research Topics

Disease

2	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2020
2	Multiple Sclerosis 02/2013 - 08/2010
2	Neuroinflammatory Diseases 02/2013 - 08/2010
2	Inflammation (Inflammations) 02/2013 - 08/2010
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2020
1	Frontotemporal Dementia (Semantic Dementia) 01/2020
1	Tauopathies 01/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/2013
1	Demyelinating Diseases (Demyelinating Disease) 08/2010
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 08/2010

Drug/Important Bio-Agent (IBA)

1	Monoclonal AntibodiesIBA 01/2020
1	tau Proteins (tau Protein)IBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2018
1	Myelin-Oligodendrocyte GlycoproteinIBA 02/2013
1	Aminobutyrates (Aminobutyric Acid)IBA 02/2013
1	gamma-Aminobutyric Acid (GABA)IBA 02/2013
1	Neurotransmitter Agents (Neurotransmitter)IBA 02/2013
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 08/2010